0.425
price up icon10.68%   0.041
pre-market  Vorhandelsmarkt:  .43   0.005   +1.18%
loading
Schlusskurs vom Vortag:
$0.384
Offen:
$0.385
24-Stunden-Volumen:
7.05M
Relative Volume:
0.29
Marktkapitalisierung:
$21.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.89M
KGV:
-0.168
EPS:
-2.53
Netto-Cashflow:
$-11.95M
1W Leistung:
+34.07%
1M Leistung:
+119.07%
6M Leistung:
-65.16%
1J Leistung:
-75.71%
1-Tages-Spanne:
Value
$0.365
$0.43
1-Wochen-Bereich:
Value
$0.3165
$0.43
52-Wochen-Spanne:
Value
$0.1634
$2.3099

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name
Firmenname
Plus Therapeutics Inc
Name
Telefon
737.255.7194
Name
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Name
Mitarbeiter
21
Name
Twitter
@plustxinc
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
PSTV's Discussions on Twitter

Vergleichen Sie PSTV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PSTV
Plus Therapeutics Inc
0.425 16.17M 0 -12.89M -11.95M -2.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-17 Eingeleitet D. Boral Capital Buy
2021-01-25 Eingeleitet Ladenburg Thalmann Buy
2020-10-16 Eingeleitet Maxim Group Buy

Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten

pulisher
02:56 AM

What analysts say about Plus Therapeutics Inc. stockSignificant capital appreciation - Autocar Professional

02:56 AM
pulisher
Jul 22, 2025

Plus Therapeutics Inc. Stock Analysis and ForecastBreakthrough stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Plus Therapeutics Inc. a good long term investmentBreakout profit opportunities - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

What drives Plus Therapeutics Inc. stock priceOutstanding yields - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo

Jul 17, 2025
pulisher
Jul 16, 2025

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases | PSTV Stock News - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

Plus Therapeutics Announces Clinical Trial Presentation and Educational Symposium at 2025 SNO/ASCO CNS Metastases Conference - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases - TradingView

Jul 15, 2025
pulisher
Jul 11, 2025

Plus Therapeutics Advances Pediatric Brain Tumor Treatment with New Clinical Study - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewswire

Jul 11, 2025
pulisher
Jul 10, 2025

Plus Therapeutics Announces Two CNSide Presentations at the Upco - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference | PSTV Stock News - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Plus Therapeutics' CNSide Showcases Innovative CSF Assay Data at SNO/ASCO CNS Metastases Conference 2025 - Nasdaq

Jul 10, 2025
pulisher
Jul 10, 2025

Revolutionary CNS Cancer Detection: Plus Therapeutics Unveils Game-Changing Clinical Data at Major Conference - Stock Titan

Jul 10, 2025
pulisher
Jul 09, 2025

Plus Therapeutics Soars 10.51% on Promising Clinical Trial Results - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Plus Therapeutics begins treatment in REYOBIQ dose optimization trial By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics begins treatment in REYOBIQ dose optimization trial - Investing.com

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases | PSTV Stock News - GuruFocus

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics announces initial patients successfully treated in ReSPECT-LM dose optimization trial for Reyobiq™ in leptomeningeal metastases - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times

Jul 08, 2025
pulisher
Jul 08, 2025

Breakthrough Brain Cancer Drug REYOBIQ Achieves 80% Tumor Reduction in Phase 1 Trial, Advances to Next Stage - Stock Titan

Jul 08, 2025
pulisher
Jul 07, 2025

Plus Therapeutics shares fall 3.72% premarket after FDA clearance of Reyobiq for childhood brain cancer. - AInvest

Jul 07, 2025
pulisher
Jul 03, 2025

Plus Therapeutics, Inc. shares fall 1.63% premarket after Novartis' Cosentyx fails in Phase III GCAptAIN study. - AInvest

Jul 03, 2025
pulisher
Jul 01, 2025

Stock under $1with a very strong catalyst to buy and hold for a minimum of three years - AInvest

Jul 01, 2025
pulisher
Jun 30, 2025

Plus Therapeutics Advances Brain Cancer Treatment: FDA Green Light and $17.6M Boost for Critical Trial - Stock Titan

Jun 30, 2025
pulisher
Jun 29, 2025

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM - GuruFocus

Jun 29, 2025
pulisher
Jun 29, 2025

PSTV SEC FilingsPlus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 29, 2025
pulisher
Jun 27, 2025

H.C. Wainwright Adjusts Price Target for Plus Therapeutics (PSTV) | PSTV Stock News - GuruFocus

Jun 27, 2025
pulisher
Jun 26, 2025

Plus Therapeutics Soars 25.71% on FDA Trial Approval - AInvest

Jun 26, 2025
pulisher
Jun 25, 2025

Plus Therapeutics (PSTV) Shares Surge After FDA Trial Clearance - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

PSTV Stock Update: D. Boral Capital Maintains Hold Rating for Plus Therapeutics | PSTV Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 24, 2025

Plus Therapeutics Announces Restructuring Of Its Equity Financing - Nasdaq

Jun 24, 2025
pulisher
Jun 20, 2025

Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN

Jun 20, 2025
pulisher
Jun 19, 2025

Plus (PSTV) Upgraded to Buy: Here's Why - Nasdaq

Jun 19, 2025
pulisher
Jun 18, 2025

Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Plus Therapeutics (PSTV) Sees Stock Dip Amid New Share Sale Fili - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering (PSTV:NASDAQ) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | P - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | PSTV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Plus Therapeutics Modifies Security Holders’ Rights - TipRanks

Jun 17, 2025
pulisher
Jun 13, 2025

Plus Therapeutics Plunges 10.89% Amid Institutional Shifts - AInvest

Jun 13, 2025
pulisher
Jun 10, 2025

Leptomeningeal Metastases Pipeline 2025: MOA, ROA, - openPR.com

Jun 10, 2025
pulisher
Jun 09, 2025

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials - AlphaStreet

Jun 09, 2025
pulisher
Jun 06, 2025

Plus Therapeutics Appeals Nasdaq Delisting Decision - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Plus Therapeutics (NASDAQ:PSTV) Given New $20.50 Price Target at Ascendiant Capital Markets - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - mx.advfn.com

Jun 05, 2025

Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):